ReviewFrontiers in pharmacology2021
The Current Application and Future Prospects of Astragalus Polysaccharide Combined With Cancer Immunotherapy: A Review.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- Advances in Bioactive Polysaccharide-Small-Molecule Drug Supramolecular Nanocomplexes for Drug Delivery and Therapeutic Applications.Journal of functional biomaterials · 2026Review
- Shengxian decoction suppresses malignant progression of lung adenocarcinoma by enhancing CD8Chinese medicine · 2026Article
- Herb-derived immunometabolic modulators: traditional Chinese medicine at the crossroads of metabolism and antitumor immunity.Chinese medicine · 2026Review
- Dietary astragalus stems polysaccharides improve antioxidant capacity and lactation performance in dairy goats through integrated metabolomic and mechanistic analyses.Scientific reports · 2026Article
- Review
- Safety Considerations for Natural Products with Adaptogenic and Immunomodulating Activities.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Deficiency of myeloid discoidin domain receptor 2 aggravates melanoma lung and bone metastasis.Investigational new drugs · 2025Article
- Pretreatment withFrontiers in pharmacology · 2025Article
- Astragalus polysaccharides: structure-immunomodulation relationships, multi-target pharmacological activities, and cutting-edge applications in immune modulation.Frontiers in immunology · 2025Review
- Article
- Network Pharmacology Based Elucidation of Molecular Mechanisms of Laoke Formula for Treatment of Advanced Non-Small Cell Lung Cancer.Chinese journal of integrative medicine · 2024Article
- Anticancer Mechanism ofPharmaceuticals (Basel, Switzerland) · 2024Review
- Self-adjuvant Astragalus polysaccharide-based nanovaccines for enhanced tumor immunotherapy: a novel delivery system candidate for tumor vaccines.Science China. Life sciences · 2024Article
- Natural plant-derived polysaccharides targeting macrophage polarization: a promising strategy for cancer immunotherapy.Frontiers in immunology · 2024Review
- Synergist for antitumor therapy: Astragalus polysaccharides acting on immune microenvironment.Discover oncology · 2023Review
- Astragalus polysaccharide ameliorates steroid-induced osteonecrosis of the femoral head by regulating miR-200b-3p-mediated Wnt/β-catenin signaling pathway via inhibiting SP1 expression : Astragalus polysaccharide regulates SONFH via SP1.BMC musculoskeletal disorders · 2023Article
- Natural polysaccharides exert anti-tumor effects as dendritic cell immune enhancers.Frontiers in oncology · 2023Review
- Application of natural polysaccharides and their novel dosage forms in gynecological cancers: therapeutic implications from the diversity potential of natural compounds.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
So far, immunotherapy has been shown to have impressive effects on different cancers in clinical trials. All those immunotherapies are generally derived from three main therapeutic approaches: immune checkpoint inhibitors, immune cell vaccination, and adoptive cellular immunotherapy. Our research systematically reviewed a wide range of clinical trials and laboratory studies of astragalus polysaccharide (APS) and elucidated the potential feasibility of using APS in activating adoptive immunotherapy. Apart from being effective in adaptive "passive" immunotherapy such as lymphokine-activated killer treatment and dendritic cell (DC)-cytokine-induced killer treatment, APS could also regulate the anti-programmed cell death protein 1 (PD-1)/PD-L1 on the surface of the immune cells, as a part in the immune checkpoint inhibitory signaling pathway by activating the immune-suppressed microenvironment by regulating cytokines, toll-like receptor 4 (TLR4), nuclear factor kappa B (NF-κB), and mitogen-activated protein kinase (MAPK) pathways, and immune cells, such as DCs, macrophages, NK cells, and so on. In view of the multiple functions of APS in immunotherapy and tumor microenvironment, a combination of APS and immunotherapy in cancer treatment has a promising prospect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.